CM Life Sciences II SPAC Merger Partner, SomaLogic, Reports FY21 Sales Expected To Exceed Previously-Issued Guidance Forecast Of $66.7M By 10+%, Gross Margins Expected To Be 500+ Basis Points Ahead Of Previous Guidance Of 51%